A Phase 2/3 interventional study of Brexpiprazole in Borderline Personality Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-03.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Borderline Personality Disorder with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Borderline Personality Disorder · United States.
Among the 81 studies in Borderline Personality Disorder with a site in United States, this one is the 11th largest by enrollment of the 71 interventional ones that give a count, is one of 5 that started in 2020, is the only one in phase 2/3, and was the 49th registered.
278 studies on the registry are indexed under Borderline Personality Disorder; 69 are open to participants now.
Browse Borderline Personality Disorder studies →15 of the 81 studies in Borderline Personality Disorder with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 22–65
Mclean Hospital · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18–60
University of California, Los Angeles · Sites in United States
Ages 18–65
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Borderline Personality Disorder studies recruiting now, 18 (38%) set no upper age limit and 29 (60%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 19 · Phase 3 6 · Phase 4 6
First in 1997; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 70 across 221 interventional studies indexed under Borderline Personality Disorder.
Median enrollment 56 across the 71 interventional studies, 48 across the 7 observational. Of the 57 that completed or were terminated, 22 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 81 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 2 studies filed under Borderline Personality Disorder — fewer than ten, so there is no comparison to draw.
7 of the studies in Borderline Personality Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04870255Stanford UniversityTreatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS | 2026-12 |
| NCT05651295Matthew Southward, PhDA Precision Medicine Approach to Target Engagement for Emotion Regulation | 2026-12-31 |
| NCT06683014Yale UniversityMDMA in Borderline Personality Disorder | 2027-06 |
| NCT07460947Mclean HospitalA Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder | 2027-06 |
| NCT06772831Icahn School of Medicine at Mount SinaiCognitive Reappraisal Training for Borderline Personality (BPD) | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 81 studies in Borderline Personality Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety and tolerability of brexpiprazole in the treatment of adults with borderline personality disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received blinded brexpiprazole 2 to 3 milligrams per day (mg/day) in the previous double-blind trial (NCT04100096), received open-label brexpiprazole 2 to 3 mg/day tablets, orally for up to 12 weeks.
Drug: Brexpiprazole
Participants who received blinded brexpiprazole matching placebo in the previous double-blind trial (NCT04100096), received open-label brexpiprazole 2 to 3 mg/day tablets, orally for up to 12 weeks.
Drug: Brexpiprazole
Administered as tablets.
Also known as: Rexulti, OPC-34712
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and as Per Severity
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered an IMP and which does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs with an onset date on or after the start of open-label treatment. The severity of AEs was graded on a 3-point scale: 1=Mild (Discomfort noticed, but no disruption to daily activity), 2=Moderate (Discomfort sufficient to reduce or affect normal daily activity), and 3=Severe (Inability to work or perform normal daily activity).
Time frame: Signing of ICF up to 30 days post last dose of study drug (up to approximately 16 weeks)
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
Potentially clinically significant ECG abnormalities included rate: Bradycardia (vent \<=50 beats per minute \[bpm\] and decrease \>=15 bpm); Rhythm: Sinus bradycardia (\<=50 bpm and decrease \>=15 bpm), absence during baseline and presence of ventricular premature beat post baseline; ST/T morphology: Absence at baseline and presence of symmetrical T-wave inversion post baseline.
Time frame: Screening up to Week 12
Number of Participants With Potentially Clinically Significant Vital Sign Abnormalities
Potentially clinically significant vital sign abnormalities included: Heart rate standing in bpm (\<50 bpm and decrease \>=15 bpm, \>120 bpm and increase \>=15 bpm); Weight in kilograms (kgs) (decrease \>=7%, increase \>=7%).
Time frame: Screening up to Week 12
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities
Potentially clinically significant laboratory abnormalities included serum chemistry: Prolactin \>upper limit of normal (ULN) (nanograms per millilitre \[ng/ml\] in males and females), fasting glucose ≥100 (milligrams per decilitre \[mg/dl\]), fasting high-density lipoprotein (HDL) cholesterol \<40 (men)/ \<50 (women) (mg/dl), fasting low-density lipoprotein (LDL) cholesterol ≥160 (mg/dl), fasting cholesterol ≥240 (mg/dl), fasting triglycerides ≥150 (mg/dl); Creatine phosphokinase (CPK)/renal: Creatine kinase \>3xULN (units per litre \[U/l\]), creatinine ≥2.0 (mg/dl), urea nitrogen ≥30 (mg/dl).
Time frame: Screening up to Week 12
Change From Baseline in Simpson-Angus Scale (SAS) Total Score
The SAS scale is used to evaluate extrapyramidal symptoms (EPS) and consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score range of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores for all 10 items, possible total score is 0 to 40. Negative change from baseline indicates less symptoms.
Time frame: Baseline and Week 12
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
The AIMS scale consists of 10 items describing symptoms of dyskinesia: Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7), dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score range of 0 (absence of symptoms) (for item 10, no awareness) to 4 (severe condition) (for item 10, awareness, severe distress). AIMS total score is the sum of the ratings for the first seven items with the possible total scores of 0 to 28. Negative change from baseline indicates less symptoms.
Time frame: Baseline and Week 12
Change From Baseline in Barnes Akathisia Rating Scale (BARS): Global Clinical Assessment of Akathisia Score
The BARS consists of 4 items related to akathisia: Objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The fourth item, global clinical evaluation was rated on a 6-point scale, with a score range of 0 (absence of symptoms) to 5 (severe akathisia). Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.
Time frame: Baseline and Week 12
Number of Participants With Suicidal Ideation and Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS was used to assess the suicidality of participants during the study. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior.
Time frame: Baseline up to Week 12
Participants were enrolled at 55 investigational sites in Spain, Ukraine, and the United States (US) from 13 January 2020 to 22 September 2021.
| Milestone | Prior Brexpiprazole 2-3 Milligrams Per Day | Prior Placebo |
|---|---|---|
| Started | 90 | 111 |
| Safety sample | 88 | 111 |
| Completed | 71 | 92 |
| Not completed | 19 | 19 |
| Withdrew: Adverse event | 1 | 8 |
| Withdrew: Lost to follow-up | 7 | 3 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 7 | 8 |
| Withdrew: Other: not related to covid-19 | 3 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered an IMP and which does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs with an onset date on or after the start of open-label treatment. The severity of AEs was graded on a 3-point scale: 1=Mild (Discomfort noticed, but no disruption to daily activity), 2=Moderate (Discomfort sufficient to reduce or affect normal daily activity), and 3=Severe (Inability to work or perform normal daily activity).
| Participants | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo |
|---|---|---|
| TEAEs | 30 | 56 |
| Mild TEAEs | 14 | 37 |
| Moderate TEAEs | 19 | 30 |
| Severe TEAEs | 3 | 4 |
Potentially clinically significant ECG abnormalities included rate: Bradycardia (vent \<=50 beats per minute \[bpm\] and decrease \>=15 bpm); Rhythm: Sinus bradycardia (\<=50 bpm and decrease \>=15 bpm), absence during baseline and presence of ventricular premature beat post baseline; ST/T morphology: Absence at baseline and presence of symmetrical T-wave inversion post baseline.
| Participants | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo |
|---|---|---|
| Bradycardia | 0 | 1 |
| Sinus Bradycardia | 0 | 1 |
| Ventricular Premature Beat | 0 | 1 |
| Symmetrical T-Wave Inversion | 0 | 1 |
Potentially clinically significant vital sign abnormalities included: Heart rate standing in bpm (\<50 bpm and decrease \>=15 bpm, \>120 bpm and increase \>=15 bpm); Weight in kilograms (kgs) (decrease \>=7%, increase \>=7%).
| Participants | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo |
|---|---|---|
| Heart Rate Standing | 3 | 1 |
| Weight Decreased | 7 | 4 |
| Weight Increased | 9 | 26 |
Potentially clinically significant laboratory abnormalities included serum chemistry: Prolactin \>upper limit of normal (ULN) (nanograms per millilitre \[ng/ml\] in males and females), fasting glucose ≥100 (milligrams per decilitre \[mg/dl\]), fasting high-density lipoprotein (HDL) cholesterol \<40 (men)/ \<50 (women) (mg/dl), fasting low-density lipoprotein (LDL) cholesterol ≥160 (mg/dl), fasting cholesterol ≥240 (mg/dl), fasting triglycerides ≥150 (mg/dl); Creatine phosphokinase (CPK)/renal: Creatine kinase \>3xULN (units per litre \[U/l\]), creatinine ≥2.0 (mg/dl), urea nitrogen ≥30 (mg/dl).
| Participants | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo |
|---|---|---|
| Prolactin (ng/ml)-Males | 1 | 0 |
| Glucose, Fasting (mg/dL) | 13 | 11 |
| HDL Cholesterol, Fasting (mg/dL) | 22 | 19 |
| LDL Cholesterol, Fasting (mg/dL) | 2 | 3 |
| Cholesterol, Fasting (mg/dL) | 2 | 7 |
| Triglycerides, Fasting (mg/dL) | 13 | 13 |
The SAS scale is used to evaluate extrapyramidal symptoms (EPS) and consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score range of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores for all 10 items, possible total score is 0 to 40. Negative change from baseline indicates less symptoms.
| score on a scale | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo |
|---|---|---|
| Baseline | 0.2 ± 0.9 | 0.1 ± 0.6 |
| Change From Baseline at Week 12 | -0.1 ± 0.7 | 0.0 ± 0.6 |
The AIMS scale consists of 10 items describing symptoms of dyskinesia: Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7), dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score range of 0 (absence of symptoms) (for item 10, no awareness) to 4 (severe condition) (for item 10, awareness, severe distress). AIMS total score is the sum of the ratings for the first seven items with the possible total scores of 0 to 28. Negative change from baseline indicates less symptoms.
| score on a scale | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo |
|---|---|---|
| Baseline | 0.0 ± 0.1 | 0.1 ± 0.8 |
| Change From Baseline at Week 12 | 0.0 ± 0.2 | -0.1 ± 0.9 |
The BARS consists of 4 items related to akathisia: Objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The fourth item, global clinical evaluation was rated on a 6-point scale, with a score range of 0 (absence of symptoms) to 5 (severe akathisia). Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.
| score on a scale | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo |
|---|---|---|
| Baseline | 0.1 ± 0.3 | 0.1 ± 0.3 |
| Change From Baseline at Week 12 | -0.1 ± 0.3 | -0.0 ± 0.5 |
C-SSRS was used to assess the suicidality of participants during the study. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior.
| Participants | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo |
|---|---|---|
| Suicidal Ideation | 28 | 28 |
| Suicidal Behavior | 0 | 2 |
Collected over Signing of ICF up to 30 days post last dose of study drug (up to approximately 16 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prior Brexpiprazole 2-3 mg/Day | 0/90 (0%) | 1/88 (1.1%) | 8/88 (9.1%) |
| Prior Placebo | 0/111 (0%) | 2/111 (1.8%) | 31/111 (27.9%) |
| Event | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo |
|---|---|---|
| Suicidal IdeationPsychiatric disorders | 1/88 | 1/111 |
| ContusionInjury, poisoning and procedural complications | 0/88 | 1/111 |
| Event | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo |
|---|---|---|
| AkathisiaNervous system disorders | 1/88 | 9/111 |
| FatigueGeneral disorders | 1/88 | 7/111 |
| RestlessnessPsychiatric disorders | 1/88 | 7/111 |
| InsomniaPsychiatric disorders | 5/88 | 6/111 |
| Weight increasedInvestigations | 0/88 | 6/111 |
Enrolled sample included all participants who signed an informed consent form (ICF) and were enrolled into the trial.
| Age, Continuous(years) | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo | Total |
|---|---|---|---|
| Mean | 33.6 ± 10.5 | 32.0 ± 10.6 | 32.7 ± 10.6 |
| Sex: Female, Male(Participants) | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo | Total |
|---|---|---|---|
| Female | 71 | 92 | 163 |
| Male | 19 | 19 | 38 |
| Race/Ethnicity, Customized(Participants) | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo | Total |
|---|---|---|---|
| Race — White | 72 | 89 | 161 |
| Race — Black or African American | 7 | 19 | 26 |
| Race — American Indian or Alaska Native | 2 | 0 | 2 |
| Race — Asian | 4 | 0 | 4 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Race — Other | 5 | 2 | 7 |
| Race/Ethnicity, Customized(Participants) | Prior Brexpiprazole 2-3 mg/Day | Prior Placebo | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 15 | 17 | 32 |
| Ethnicity — Not Hispanic or Latino | 75 | 93 | 168 |
| Ethnicity — Other | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Jan 2020 to primary completion in Sep 2021, 20 months.
Results were first posted in Oct 2024, 3 years after primary completion. A results delay was requested in Sep 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Borderline Personality Disorder →
Otsuka Pharmaceutical Development & Commercialization, Inc. →